曲伐沙星（CP-99,219）、司帕沙星、环丙沙星和氟罗沙星对呼吸道病原体的体外活性。 - Suppr

Suppr

超能文献

In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.

作者信息

Crokaert F, Aoun M, Duchateau V, Grenier P, Vandermies A, Klastersky J

机构信息

Institut Jules Bordet, Internal, University of Brussels, Belgium.

出版信息

Eur J Clin Microbiol Infect Dis. 1996 Aug;15(8):696-8. doi: 10.1007/BF01691164.

DOI:10.1007/BF01691164

PMID:8894585

Abstract

摘要

相似文献

In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.

Eur J Clin Microbiol Infect Dis. 1996 Aug;15(8):696-8. doi: 10.1007/BF01691164.

[In vitro activity of trovafloxacin in 238 respiratory pathogens].

Rev Esp Quimioter. 1998 Mar;11(1):47-51.

Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.

Int J Antimicrob Agents. 2001 Oct;18(4):379-82. doi: 10.1016/s0924-8579(01)00419-8.

Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.

J Antimicrob Chemother. 1997 Mar;39(3):411-4. doi: 10.1093/jac/39.3.411.

Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.

J Chemother. 2002 Feb;14(1):19-24. doi: 10.1179/joc.2002.14.1.19.

Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project.

J Antimicrob Chemother. 2000 Jul;46 Suppl T1:11-5. doi: 10.1093/oxfordjournals.jac.a020888.

Comparative in-vitro activity of CP-99219, a new quinolone, against respiratory pathogens.

J Antimicrob Chemother. 1996 Apr;37(4):803-8. doi: 10.1093/jac/37.4.803.

Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.

Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):413-9. doi: 10.1007/BF01691574.

In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.

J Antimicrob Chemother. 1997 Sep;40(3):427-31. doi: 10.1093/jac/40.3.427.

Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.

J Antimicrob Chemother. 2001 May;47(5):681-4. doi: 10.1093/jac/47.5.681.

引用本文的文献

The new fluoroquinolones: A critical review.

Can J Infect Dis. 1999 May;10(3):207-38. doi: 10.1155/1999/378394.

Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. Trovafloxacin Bronchitis Study Group.

Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):441-6. doi: 10.1007/BF01691580.

An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin.

Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):431-3. doi: 10.1007/BF01691578.

Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.

Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):405-12. doi: 10.1007/BF01691573.

In vitro activity of trovafloxacin against Chlamydia pneumoniae.

Antimicrob Agents Chemother. 1997 Sep;41(9):2033-4. doi: 10.1128/AAC.41.9.2033.

本文引用的文献

Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).

Antimicrob Agents Chemother. 1996 Jan;40(1):47-9. doi: 10.1128/AAC.40.1.47.

In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.

Antimicrob Agents Chemother. 1995 Oct;39(10):2210-6. doi: 10.1128/AAC.39.10.2210.

Lower respiratory tract infection therapy--the role of ciprofloxacin.

J Int Med Res. 1995 Sep-Oct;23(5):315-27. doi: 10.1177/030006059502300501.

New quinolones and gram-positive bacteria.

Antimicrob Agents Chemother. 1994 Feb;38(2):163-9. doi: 10.1128/AAC.38.2.163.

In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.

Antimicrob Agents Chemother. 1994 Jun;38(6):1402-3. doi: 10.1128/AAC.38.6.1402.

In vitro activity of the new fluoroquinolone CP-99,219.

Antimicrob Agents Chemother. 1994 Nov;38(11):2615-22. doi: 10.1128/AAC.38.11.2615.

Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.

Antimicrob Agents Chemother. 1995 Jun;39(6):1243-6. doi: 10.1128/AAC.39.6.1243.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验